Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Drug metabolism and disposition: the biological fate of chemicals - 1 Apr 2013

Edavana Vineetha Koroth, Dhakal Ishwori B, Williams Suzanne, Penney Rosalind, Boysen Gunnar, Yao-Borengasser Aiwei, Kadlubar Susan

Abstract excerpt

Anastrozole belongs to the nonsteroidal triazole-derivative group of aromatase inhibitors. Recently, clinical trials demonstrated improved antitumoral efficacy and a favorable toxicity with third-generation aromatase inhibitors, compared with tamoxifen. Anastrozole is predominantly metabolized by phase I oxidation with the potential for further phase II glucuronidation. It also, however, is subject to direct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inactivation, Metabolic

Share to Lamotrigine

Share to Microsomes, Liver

Share to Nitriles

Share to Triazines

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 23371966
DOI: 10.1124/dmd.112.048157
PMCID: PMC3608453

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.PMID 23371966Read ↗

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.Semantic proximity Read ↗

UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.Semantic proximity Read ↗

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.Semantic proximity Read ↗

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.Semantic proximity Read ↗

Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.Semantic proximity Read ↗

Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family.Semantic proximity Read ↗

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of TamoxifenSemantic proximity Read ↗

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.